Should I buy or sell Sight Sciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sight Sciences in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SGHT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGHT, but not buy additional shares or sell existing shares. View SGHT analyst ratings or view top-rated stocks .

What is Sight Sciences' stock price target for 2024?

7 brokerages have issued 1 year target prices for Sight Sciences' stock. Their SGHT share price targets range from $4.00 to $5.50. On average, they expect the company's share price to reach $4.60 in the next twelve months. This suggests that the stock has a possible downside of 13.0%. View analysts price targets for SGHT or view top-rated stocks among Wall Street analysts .

How have SGHT shares performed in 2024?

Sight Sciences' stock was trading at $5.16 at the beginning of the year. Since then, SGHT shares have increased by 2.5% and is now trading at $5.29. View the best growth stocks for 2024 here .

Are investors shorting Sight Sciences?

Sight Sciences saw a decline in short interest in March. As of March 31st, there was short interest totaling 1,290,000 shares, a decline of 20.9% from the March 15th total of 1,630,000 shares. Based on an average trading volume of 215,100 shares, the short-interest ratio is presently 6.0 days. Approximately 4.9% of the company's stock are short sold. View Sight Sciences' Short Interest .

When is Sight Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our SGHT earnings forecast .

How can I listen to Sight Sciences' earnings call?

Sight Sciences will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Sight Sciences' earnings last quarter?

Sight Sciences, Inc. (NASDAQ:SGHT) released its quarterly earnings results on Thursday, March, 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.13. The company had revenue of $18.75 million for the quarter, compared to analyst estimates of $18.70 million. Sight Sciences had a negative net margin of 68.53% and a negative trailing twelve-month return on equity of 41.94%. During the same period in the prior year, the firm earned ($0.35) EPS.

What guidance has Sight Sciences issued on next quarter's earnings?

Sight Sciences updated its FY 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $81.0 million-$85.0 million, compared to the consensus revenue estimate of $82.4 million.

When did Sight Sciences IPO?

Sight Sciences (SGHT) raised $150 million in an initial public offering on Thursday, July 15th 2021. The company issued 6,980,000 shares at $20.00-$23.00 per share.

How do I buy shares of Sight Sciences?

Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SGHT

Sight Sciences (SGHT) Stock Price, News & Analysis

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)

Free SGHT Stock Alerts

$5.05

-0.19 (-3.63%)

(As of 02:45 PM ET)

Compare

Today's Range: $5.05
▼
$5.45
50-Day Range: $4.02
▼
$6.10
52-Week Range: $1.04
▼
$11.20

Volume: 61,363 shs
Average Volume: 223,586 shs
Market Capitalization: $250.23 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.60

Get Sight Sciences alerts:

Sight Sciences MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 13.0% Downside
$4.60 Price Target
Short Interest: Healthy
4.93% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.48
Based on 4 Articles This Week
Insider Trading: Selling Shares
$173,375 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.04) to ($0.95) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.81 out of 5 stars

Medical Sector

833rd out of 918 stocks

Surgical & Medical Instruments Industry

87th out of 97 stocks

1.0

Analyst's Opinion

Consensus Rating
Sight Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 5 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Sight Sciences has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.93% of the float of Sight Sciences has been sold short.
Short Interest Ratio / Days to Cover
Sight Sciences has a short interest ratio ("days to cover") of 6.
Change versus previous month
Short interest in Sight Sciences has recently decreased by 20.86%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sight Sciences does not currently pay a dividend.
Dividend Growth
Sight Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SGHT.

2.5

News and Social Media Coverage

News Sentiment
Sight Sciences has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Sight Sciences this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for SGHT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
2 people have added Sight Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sight Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,375.00 in company stock.
Percentage Held by Insiders
27.10% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sight Sciences are expected to grow in the coming year, from ($1.04) to ($0.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sight Sciences is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sight Sciences is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sight Sciences has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About Sight Sciences Stock (NASDAQ:SGHT)

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

SGHT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SGHT Stock News Headlines

April 5, 2024 | insidertrades.com

Insider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells 3,128 Shares of Stock

April 18, 2024 | globenewswire.com

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

April 19, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 13, 2024 | americanbankingnews.com

Sight Sciences, Inc. (NASDAQ:SGHT) Receives $4.60 Consensus Price Target from Analysts

April 12, 2024 | investing.com

Sight Sciences reports glaucoma surgery study results

April 11, 2024 | americanbankingnews.com

Needham & Company LLC Reaffirms "Hold" Rating for Sight Sciences (NASDAQ:SGHT)

April 10, 2024 | globenewswire.com

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

April 2, 2024 | globenewswire.com

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 19, 2024 | DTI (Ad)

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more

Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…

March 27, 2024 | finance.yahoo.com

Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

March 26, 2024 | globenewswire.com

Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

March 16, 2024 | finance.yahoo.com

SGHT Apr 2024 5.000 call

March 8, 2024 | finance.yahoo.com

Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2023 Earnings Call Transcript

March 8, 2024 | finance.yahoo.com

Q4 2023 Sight Sciences Inc Earnings Call

March 7, 2024 | finance.yahoo.com

Sight Sciences Inc (SGHT) Navigates Challenges to Maintain Revenue Growth and Reduce Expenses

March 7, 2024 | investorplace.com

SGHT Stock Earnings: Sight Sciences Beats EPS, Misses Revenue for Q4 2023

March 7, 2024 | benzinga.com

Sight Sciences: Q4 Earnings Insights

March 7, 2024 | msn.com

Sight Sciences GAAP EPS of -$0.22 beats by $0.12, revenue of $18.8M misses by $0.6M

March 7, 2024 | globenewswire.com

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

March 6, 2024 | benzinga.com

Sight Sciences's Earnings: A Preview

February 23, 2024 | finance.yahoo.com

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

February 23, 2024 | finance.yahoo.com

UVM Health Network and UnitedHealthcare reach last minute agreement on coverage

February 22, 2024 | globenewswire.com

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

February 21, 2024 | finance.yahoo.com

Ten-Year Low Volatility Has Locals Piling Into Brazilian Real

February 21, 2024 | finance.yahoo.com

Sight Sciences (SGHT) to Expand in Europe With New Launch

February 16, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Integer Holdings (ITGR) and Pacific Biosciences (PACB)

February 15, 2024 | finanznachrichten.de

Sight Sciences, Inc.: Sight Sciences Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting

See More Headlines

Receive SGHT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sight Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:SGHT
CUSIP: N/A
CIK: 1531177
Web: www.sightsciences.com
Phone: 877-266-1144
Fax: N/A
Employees: 214
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.60
High Stock Price Target: $5.50
Low Stock Price Target: $4.00
Potential Upside/Downside: -12.2%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-55,550,000.00
Net Margins: -68.53%
Pretax Margin: -68.39%
Return on Equity: -41.94%
Return on Assets: -30.64%

Debt

Debt-to-Equity Ratio: 0.26
Current Ratio: 13.29
Quick Ratio: 12.65

Sales & Book Value

Annual Sales: $81.06 million
Price / Sales: 3.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.47 per share
Price / Book: 2.12

Miscellaneous

Outstanding Shares: 49,550,000
Free Float: 36,124,000
Market Cap: $259.64 million
Optionable: Optionable
Beta: 2.83

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Paul Badawi (Age 49)
Co-Founder, President, CEO & Director
Comp: $920.3k
Dr. David Badawi M.D. (Age 54)
Founder, CTO & Director
Mr. Sam Boong Park (Age 63)
Chief Operating Officer
Comp: $531.78k
Ms. Alison Perry Bauerlein (Age 43)
CFO & Treasurer
Mr. Jeremy B. Hayden (Age 54)
Chief Legal Officer
Mr. Steve R. Tamayo Jr.
VP and Chief Ethics & Compliance Officer
Dr. Reay H. Brown
Chief Medical Officer
Tom Huang
Head of Corporate Strategy & Development
Mr. Matthew W. Link (Age 49)
Chief Commercial Officer
Mr. Stephen B. Thau J.D.
Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SGHT Stock Analysis - Frequently Asked Questions

Should I buy or sell Sight Sciences stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sight Sciences in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SGHT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGHT, but not buy additional shares or sell existing shares.
View SGHT analyst ratings or view top-rated stocks.
What is Sight Sciences' stock price target for 2024?: 7 brokerages have issued 1 year target prices for Sight Sciences' stock. Their SGHT share price targets range from $4.00 to $5.50. On average, they expect the company's share price to reach $4.60 in the next twelve months. This suggests that the stock has a possible downside of 13.0%.
View analysts price targets for SGHT or view top-rated stocks among Wall Street analysts.
How have SGHT shares performed in 2024?: Sight Sciences' stock was trading at $5.16 at the beginning of the year. Since then, SGHT shares have increased by 2.5% and is now trading at $5.29.
View the best growth stocks for 2024 here.
Are investors shorting Sight Sciences?: Sight Sciences saw a decline in short interest in March. As of March 31st, there was short interest totaling 1,290,000 shares, a decline of 20.9% from the March 15th total of 1,630,000 shares. Based on an average trading volume of 215,100 shares, the short-interest ratio is presently 6.0 days. Approximately 4.9% of the company's stock are short sold.
View Sight Sciences' Short Interest.
When is Sight Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our SGHT earnings forecast.
How can I listen to Sight Sciences' earnings call?: Sight Sciences will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Sight Sciences' earnings last quarter?: Sight Sciences, Inc. (NASDAQ:SGHT) released its quarterly earnings results on Thursday, March, 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.13. The company had revenue of $18.75 million for the quarter, compared to analyst estimates of $18.70 million. Sight Sciences had a negative net margin of 68.53% and a negative trailing twelve-month return on equity of 41.94%. During the same period in the prior year, the firm earned ($0.35) EPS.
What guidance has Sight Sciences issued on next quarter's earnings?: Sight Sciences updated its FY 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $81.0 million-$85.0 million, compared to the consensus revenue estimate of $82.4 million.
When did Sight Sciences IPO?: Sight Sciences (SGHT) raised $150 million in an initial public offering on Thursday, July 15th 2021. The company issued 6,980,000 shares at $20.00-$23.00 per share.
How do I buy shares of Sight Sciences?: Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SGHT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial